Absci Corporation harnesses generative AI to design novel proteins for drug discovery. Its platform accelerates development by predicting and validating therapeutic candidates in silico. Pharmaceutical companies and biotech researchers benefit from faster, more efficient creation of antibody-based treatments, potentially reducing years of lab work and clinical trial risks.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends